Key facts
- This page summarizes Steve Aselage's Form 4 filing for BIOCRYST PHARMACEUTICALS INC (BCRX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 14 Jun 2024, 16:20.
Steve Aselage - 12 Jun 2024 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)
- Reporting relationship
- Director
- Issuer ticker
- BCRX
- Reported as of
- 12 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 14 Jun 2024, 16:20:58 UTC
- Prior SEC filing
- 29 May 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Alane P. Barnes, by power of attorney
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Steve Aselage filed Form 4 for BIOCRYST PHARMACEUTICALS INC (BCRX) on 14 Jun 2024.
Change
- Previous filing in this sequence was filed on 29 May 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BCRX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +6,820
- Change %
- +11%
- Price
- $0.000000
- Shares after
- 70,159
- Date
- 12 Jun 2024
- Ownership
- Direct
- Footnotes
- F1
BCRX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 2,500
- Date
- 12 Jun 2024
- Ownership
- By Trust
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BCRX
transaction
Derivative
Automatic Stock Option Grant
Award
- Transaction value
- $0
- Shares
- +49,933
- Change %
- Price
- $0.000000
- Shares after
- 49,933
- Date
- 12 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 49,933
- Exercise price
- $6.30
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.
Footnote F2
Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.